tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2014 Oct 8. pii: CVI.00547-14. [Epub ahead of print]
Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Vaccine Assessment.
Skinner JA1, Zurawski SM1, Sugimoto C2, Vinet-Oliphant H2, Vinod P1, Xue Y1, Russel-Lodrigue K2, Albrecht RA3, Garc?a-Sastre A3, Salazar AM4, Roy CJ2, Kuroda MJ2, Oh S1, Zurawski G5.
Author information
Abstract
Despite the availability of annually formulated vaccines, influenza infection remains a worldwide public health burden. Therefore, it is important to develop preclinical challenge models that allow evaluation of vaccine candidates while informing on the mechanisms of protection. Here, we report that na?ve rhesus macaques challenged with 2009 pandemic H1N1 (pH1N1) do not develop observable clinical symptoms of disease, but develop a subclinical biphasic fever on day 1 and days 5-6 post-challenge. Whole blood microarray analysis further revealed that interferon activity was associated with fever. We then tested whether type 1 interferon activity in the blood is a correlate of the efficacy of vaccines. Animals immunized with candidate vaccines carrying hemagglutinin (HA) or nucleoprotein (NP) exhibited significantly reduced interferon activity on days 5-6 post-challenge. Supported by cellular and serological data, we conclude that blood interferon activity is a prominent marker that provides a convenient metric of influenza vaccine efficacy in the subclinical rhesus macaque model.
Copyright ? 2014, American Society for Microbiology. All Rights Reserved.
PMID:
25298110
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25298110
Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Vaccine Assessment.
Skinner JA1, Zurawski SM1, Sugimoto C2, Vinet-Oliphant H2, Vinod P1, Xue Y1, Russel-Lodrigue K2, Albrecht RA3, Garc?a-Sastre A3, Salazar AM4, Roy CJ2, Kuroda MJ2, Oh S1, Zurawski G5.
Author information
Abstract
Despite the availability of annually formulated vaccines, influenza infection remains a worldwide public health burden. Therefore, it is important to develop preclinical challenge models that allow evaluation of vaccine candidates while informing on the mechanisms of protection. Here, we report that na?ve rhesus macaques challenged with 2009 pandemic H1N1 (pH1N1) do not develop observable clinical symptoms of disease, but develop a subclinical biphasic fever on day 1 and days 5-6 post-challenge. Whole blood microarray analysis further revealed that interferon activity was associated with fever. We then tested whether type 1 interferon activity in the blood is a correlate of the efficacy of vaccines. Animals immunized with candidate vaccines carrying hemagglutinin (HA) or nucleoprotein (NP) exhibited significantly reduced interferon activity on days 5-6 post-challenge. Supported by cellular and serological data, we conclude that blood interferon activity is a prominent marker that provides a convenient metric of influenza vaccine efficacy in the subclinical rhesus macaque model.
Copyright ? 2014, American Society for Microbiology. All Rights Reserved.
PMID:
25298110
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25298110